1. Generics Bulletin
  2. >>Business

Teva Makes It Six With Kentucky Price-Fixing Settlement, As Trial Draws Nearer

Amount Aligns With Framework, Proportional To Share Of US Population

 
• By Dean Rudge

Teva is continuing to knock down one-by-one US state price fixing-claims, with the prospect of a criminal trial beginning in May next year.

Price_Fixing_Investigation_2020
• Source: Citeline

Teva has agreed to settle price-fixing claims lodged by the state of Kentucky, the sixth such settlement the Israeli firm has reached in the US so far, with a $1.407m payment that will dismiss all claims against Teva and its affiliates once payment has been made.

The amount aligns with the framework Teva has followed to date, paying each state an amount proportional to its share of the national population

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

Viatris Awaits ‘Significant Rebound’ At Indore In 2026 After Painful Q1 Bite

 
• By Dean Rudge

Viatris continues to make progress on remediation at the firm’s stricken manufacturing facility in Indore, India, following a warning letter and import alert delivered at the tail end of 2024.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.